A Pfizer manufacturing site for injectable drugs, Hospira Healthcare in Tamil Nadu, India, has received a 32-page Form 483 from the FDA.
A Pfizer manufacturing site for injectable drugs, Hospira Healthcare in Tamil Nadu, India, has received a 32-page Form 483 from the FDA, noting 11 inspection observations.
The citations identified several manufacturing and quality control issues with the plant, including the following:
Hospira, which was acquired by Pfizer in 2015, has been the subject of several 483s and FDA warning letters in manufacturing sites outside of India as well, specifically across the Americas, as well as in Italy. Additionally, according to Pfizer, Hospira has issued 11 nationwide recalls in the United States since 2010.
“We’re disappointed with the outcome of a recent regulatory inspection at our manufacturing facility. We have submitted a comprehensive response to the FDA and are committed to implementing the necessary improvements and to ensuring the quality of our medicines,” said Pfizer spokesperson Steve Danehy, in a recent interview. “Pfizer is committed to product quality and we have voluntarily paused production at our Irungattukottal, India site.”
In addition to its other products, Pfizer currently has 6 biosimilars in registration or phase 3 development, including an adalimumab referencing Humira, a bevacizumab referencing Avastin, an epoetin alfa referencing Epogen and Procrit, a filgrastim referencing Neupogen, a rituximab referencing Rituxan/MabThera, and a trastuzumab referencing Herceptin. However, the Hospira plant is not involved in the manufacturing of biosimilars.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.